Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Aug 2015 09:14

RNS Number : 2142W
GW Pharmaceuticals PLC
17 August 2015
 



 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

119,050 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

72,150 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

46,900 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

200,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

122,613 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

312,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

755,473 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

56,978 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

800,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JANUARY 2015

500,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

208,550 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

2,800 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

205,750 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

168,650 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

784,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

1,021,408 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

763,043 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

1,000,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1223 266800

 

James Steel/Clare Terlouw, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRVDLBFEVFFBBX
Date   Source Headline
18th Feb 201410:20 amRNSBlocklisting Interim Review
12th Feb 20141:47 pmRNSAdditional Listing
10th Feb 20145:00 pmRNSPresenting at Leerink Global Healthcare Conference
5th Feb 20147:00 amRNSQ1 2014 Financial Results and Operational Progress
31st Jan 20143:17 pmRNSHolding(s) in Company
29th Jan 20147:00 amRNSNotice of Results
17th Jan 20145:11 pmRNSHolding(s) in Company
16th Jan 201411:13 amRNSAdditional Listing
15th Jan 20144:34 pmRNSHolding(s) in Company
15th Jan 20144:33 pmRNSHolding(s) in Company
14th Jan 20144:23 pmRNSClosing of U.S. Follow-on Offering of Nasdaq ADSs
14th Jan 20147:00 amRNSAgreement with Ipsen for Sativex in Latin America
13th Jan 20145:00 pmRNSHolding(s) in Company
13th Jan 20145:00 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSRaises $87.9m on NASDAQ in U.S. Follow-On Offering
6th Jan 201412:18 pmRNSResults of General Meeting
6th Jan 201412:13 pmRNSFiles Amendment to Registration Statement
20th Dec 20132:05 pmRNSNotice of General Meeting and Follow-On Offering
11th Dec 20137:00 amRNSU.S. Patent Allowance for Cannabinoids in Glioma
6th Dec 20135:52 pmRNSPublication of UK Annual Report and Accounts
2nd Dec 20137:00 amRNSPresenting at Piper Jaffray Health Care Conference
29th Nov 20132:00 pmRNSBlocklisting Application
27th Nov 20137:00 amRNSSativex Regulatory Approval in Switzerland
26th Nov 20135:51 pmRNSDirector/PDMR Shareholding
26th Nov 20137:00 amRNSFiling of U.S. Annual Report on Form 20-F
19th Nov 20137:00 amRNSFinal Results
18th Nov 20136:00 pmRNSGW Presenting at Jefferies Healthcare Conference
15th Nov 20137:00 amRNSUpdate on Epidiolex in Childhood Epilepsy
12th Nov 20137:01 amRNSNotice of Results
11th Nov 20137:00 amRNSPhase 1b/2a trial for Glioblastoma Multiforme
21st Oct 20137:00 amRNSSuccessful Closing of Mutual Recognition Procedure
2nd Oct 20138:00 amRNSNew Sativex Data at ECTRIMS
24th Sep 20132:01 pmRNSGrant of Options
23rd Sep 201311:41 amRNSAgreement on Sativex Pricing in Germany
20th Sep 20137:00 amRNSPresenting at Aegis Capital Healthcare Conference
18th Sep 20137:00 amRNSGW Commences Trial of GWP42006 for Epilepsy
19th Aug 20137:00 amRNSBlocklisting Interim Review
14th Aug 20137:00 amRNSInvestigational New Drug Application for Sativex
8th Aug 20137:00 amRNSPresenting at the Canaccord Genuity Conference
5th Aug 20137:00 amRNS2013 Third Quarter Financial Results
5th Aug 20137:00 amRNSSativex MS Spasticity Cognition Study Results
22nd Jul 20137:00 amRNSFiles new application to expand Sativex to France
15th Jul 20137:00 amRNSNotice of Results
8th Jul 20137:00 amRNSProduct Launch
4th Jul 20138:31 amRNSHolding(s) in Company
10th Jun 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jun 20137:00 amRNSSecond Quarter Financial Results
30th May 20135:30 pmRNSExercise of Over-Allotment Option
14th May 20131:00 pmRNSNotice of Results
10th May 20134:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.